This study, published in the journal Vaccine, evaluated the safety of the RTS,S/AS02A malaria vaccine in a proof of concept Phase IIb trial in Mozambican children aged one to four years. Overall, the study results indicate that the vaccine has a good safety profile and is well tolerated when given in three doses to semi-immune children living in malaria-endemic areas.

Author(s): Sacarlal J, Aponte JJ, Aide P, et al.

Published: 2008

Resource types: Peer-reviewed journal

Diseases: Malaria

Topics: Vaccine safety; Disease/vaccine specific information

Regions: Africa